Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial

ReSTORE trial investigators

Research output: Contribution to journalArticlepeer-review

50 Scopus citations

Abstract

Background: Rezafungin is a next-generation, once-a-week echinocandin in development for the treatment of candidaemia and invasive candidiasis and for the prevention of invasive fungal disease caused by Candida, Aspergillus, and Pneumocystis spp after blood and marrow transplantation. We aimed to compare the efficacy and safety of intravenous rezafungin versus intravenous caspofungin in patients with candidaemia and invasive candidiasis. Methods: ReSTORE was a multicentre, double-blind, double-dummy, randomised phase 3 trial done at 66 tertiary care centres in 15 countries. Adults (≥18 years) with systemic signs and mycological confirmation of candidaemia or invasive candidiasis were eligible for inclusion and randomly assigned (1:1) to receive intravenous rezafungin once a week (400 mg in week 1, followed by 200 mg weekly, for a total of two to four doses) or intravenous caspofungin (70 mg loading dose on day 1, followed by 50 mg daily) for no more than 4 weeks. The primary endpoints were global cure (consisting of clinical cure, radiological cure, and mycological eradication) at day 14 for the European Medical Agency (EMA) and 30-day all-cause mortality for the US Food and Drug Administration (FDA), both with a target non-inferiority margin of 20%, assessed in the modified intention-to-treat population (all patients who received one or more doses of study drug and had documented Candida infection based on a culture from blood or another normally sterile site obtained within 96 h before randomisation). Safety was evaluated by the incidence and type of adverse events and deaths in the safety population, defined as all patients who received any amount of study drug. The trial is registered with ClinicalTrials.gov, NCT03667690, and is complete. Findings: Between Oct 12, 2018, and Aug 29, 2021, 222 patients were screened for inclusion, and 199 patients (118 [59%] men; 81 [41%] women; mean age 61 years [SD 15·2]) were randomly assigned (100 [50%] patients to the rezafungin group and 99 [50%] patients to the caspofungin group). 55 (59%) of 93 patients in the rezafungin group and 57 (61%) of 94 patients in the caspofungin group had a global cure at day 14 (weighted treatment difference −1·1% [95% CI −14·9 to 12·7]; EMA primary endpoint). 22 (24%) of 93 patients in the rezafungin group and 20 (21%) of 94 patients in the caspofungin group died or had an unknown survival status at day 30 (treatment difference 2·4% [95% CI −9·7 to 14·4]; FDA primary endpoint). In the safety analysis, 89 (91%) of 98 patients in the rezafungin group and 83 (85%) of 98 patients in the caspofungin group had at least one treatment-emergent adverse event. The most common treatment-emergent adverse events that occurred in at least 5% of patients in either group were pyrexia, hypokalaemia, pneumonia, septic shock, and anaemia. 55 (56%) patients in the rezafungin group and 52 (53%) patients in the caspofungin group had serious adverse events. Interpretation: Our data show that rezafungin was non-inferior to caspofungin for the primary endpoints of day-14 global cure (EMA) and 30-day all-cause mortality (FDA). Efficacy in the initial days of treatment warrants evaluation. There were no concerning trends in treatment-emergent or serious adverse events. These phase 3 results show the efficacy and safety of rezafungin and support its ongoing development. Funding: Cidara Therapeutics and Mundipharma.

Original languageEnglish (US)
Pages (from-to)49-59
Number of pages11
JournalThe Lancet
Volume401
Issue number10370
DOIs
StatePublished - Jan 7 2023

Bibliographical note

Funding Information:
The ReSTORE trial was cofunded by Cidara Therapeutics (San Diego, CA, USA) and Mundipharma (Cambridge, UK). The authors thank the investigators, trial personnel, and patients who made the ReSTORE trial possible. A list of contributing ReSTORE Trial Investigators is provided in the appendix (pp 14–17 ). The authors also thank Thierry Calandra, Carol Kauffman, and Luis Ostrosky-Zeichner for their contributions as members of the independent data and safety monitoring board, and Malathi Shivaprakash for DSMB coordination. Special thanks to Luis Ostrosky-Zeichner for his contributions to the trial design and to Laura Navalta, Karen Mena, Gordana Schnider, and Lorena Kanu. Thanks also go to Kevin Garey, Russel Lewis, Johan Maertens, Kieran Marr, Andrej Spec, George R Thompson, Matteo Bassetti, Oliver Cornely, Patrick M Honore, Marin Kollef, Bart Jan Kullberg, Alex Soriano, Peter G Pappas, and Jose A Vazquez for their valuable advice and insights as members of the ReSTORE scientific publications steering committee. Writing and editorial assistance was provided by Merry H Saba (Cidara Therapeutics) on outline development; by Thomas Owens, PhD, (Aspire Scientific) on submission preparation and author and contributor coordination with funding by Cidara Therapeutics; and by Tressa Chung (Cidara Therapeutics [at the time work was completed]).

Publisher Copyright:
© 2023 Elsevier Ltd

Fingerprint

Dive into the research topics of 'Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial'. Together they form a unique fingerprint.

Cite this